Please login to the form below
Former Novartis vaccines CMO joins Arterial
Dr Markus Weissbach becomes clinical trials director
Arterial Capital Management, a life science-focused private equity firm, has appointed Dr Markus Weissbach as clinical trials director and a member of its board.
Dr Weissback brings over 25 years of life science industry experience to the post - with particular expertise in cardiology, infectious diseases and oncology - and is currently chief operating officer at DS Biopharma in Dublin.
He recently served as chief medical officer at Novartis Vaccines and Diagnostics, and chief executive officer of Averion International.
Prior to this Weissbach was a director at Takeda Europe, with responsibility for its clinical research and development unit. He also brings expertise from Knoll, CytoTools Biotech, Vasopharm, Cardiorentis, BernaBiotech and Sunesis.
David Evans, director of Arterial, said: “The ability to convert strong science and supporting data into strong investor returns is what makes an outstanding private equity business.
“The addition of Markus to our team is fantastic news for investors and investees alike.”
Subscribe to our email news alerts
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen reports positive results for Otezla in psoriatic arthritis
- Merck sues US government over Medicare drug price negotiation programme
- GSK’s RSV vaccine approved by EC for older adults
- The 17th World Congress on Controversies in Neurology
- Medscape Education is Focusing on Patient Centricity and Education Outcomes at EHA 2023
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
No results were found
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
